Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2016

01-06-2016 | Research Article

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Authors: M. Ozcelik, H. Odabas, O. Ercelep, S. Yuksel, A. G. Mert, D. Aydin, H. Surmeli, D. Isik, S. Isik, A. Oyman, B. B. Oven Ustaalioglu, M. Aliustaoglu, M. Gumus

Published in: Clinical and Translational Oncology | Issue 6/2016

Login to get access

Abstract

Aim

The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens.

Materials and methods

Seventy years and older patients with metastatic colorectal carcinoma were included in this retrospective study. Bevacizumab was administered at a dose of 7.5 mg/kg on day 1 as an intravenous (IV) infusion over 30–90 min every 21 days, and capecitabine was prescribed at 1000 mg/m2 twice daily on days 1–14 of the same 21-day schedule.

Results

Eighty-two consecutive patients (47 men, 35 women) were included in the study. The mean age was 75.5 (SD 3.9, range 70–87). Half of the patients were older than 75 years. There were 55 patients (67.1 %) with a good Eastern Cooperative Oncology Group (ECOG) performance status (PS: 0–1) and the remaining 27 patients (32.9 %) had a poor ECOG performance status (PS: 2). With a median follow-up period of 18.5 months, the median progression-free survival (PFS) was 10 months (95 % CI, 7.8–12.1) and the median OS was 25 months (95 % CI, 18.6–31.3). The main toxicities recorded were non-hematological. Thirty-one patients (37 %) experienced grade 3/4 adverse events, the most common being hand–foot syndrome (9.8 %). No fatal toxicity resulting from this regimen was recorded.

Conclusions

Considering the toxicity profile and survival outcomes, the combination regimen of capecitabine and bevacizumab is a potentially feasible treatment option in elderly mCRC patients.
Literature
1.
Tournigand C, Andre T, Acille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.CrossRefPubMed
2.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.CrossRefPubMed
3.
Van Cutsem E, Nordlinger B, Cervantes A, on behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21(suppl 5):v93–7.
4.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8.CrossRefPubMed
5.
Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev. 2006;32:1–8.CrossRefPubMed
6.
Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.CrossRefPubMed
7.
Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.CrossRefPubMed
8.
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14:1735–43.CrossRefPubMed
9.
Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291–7.CrossRefPubMed
10.
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282–92.PubMed
11.
Douillard JY, Sobrero A, Carnaghi C, Comella P, Díaz-Rubio E, Santoro A, et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol. 2003;14(Suppl2):7–12.
12.
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMed
13.
Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;23:N16S.
14.
Kozloff MF, Sugrue MM, Purdie DM, Berlin JD, Flynn PJ, Kabbinavar F, et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: results from the BRITE Prospective Cohort Study. J Clin Oncol. 2008;26:184s.
15.
16.
National Cancer Institute. Surveillance, epidemiology, and end results. National Cancer Institute: Bethesda; 2007.
17.
Anisimov VN. Biological interactions of aging and carcinogenesis. Cancer Treat Res. 2005;124:17–50.CrossRefPubMed
18.
Feliu J, Escudero P, Llosa F, Bolanos M, Vicent JM, Yubero A, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005;23(13):3104–11.CrossRefPubMed
19.
Feliu J, Safont MJ, Salud A, Losa F, Garcia-Giron C, Bosch C, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 2010;102:1468–73.CrossRefPubMedPubMedCentral
20.
Vrdoljak E, Omrcen T, Boban M, Hrabar A. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs. 2011;22:191–7.CrossRefPubMed
21.
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase III trial. Lancet. 2013;14:1077–85.CrossRefPubMed
22.
Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the treatment of digestive tumors study. J Clin Oncol. 2005;23(15):3545–51.CrossRefPubMed
23.
Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer. 2004;91(8):1453–8.CrossRefPubMedPubMedCentral
24.
Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24(25):4085–91.CrossRefPubMed
25.
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.CrossRefPubMed
26.
Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRITE observational cohort study. Oncology. 2010;78:329–39.CrossRefPubMed
27.
Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 2012;23(6):1531–6.CrossRefPubMed
28.
Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009;27(2):199–205.CrossRefPubMed
29.
Kronborg CS, Jensen AR. Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy. Int J Colorectal Dis. 2015;30(8):1059–65.CrossRefPubMed
30.
Khanfir A, Feki J, Zidi Z, Masmoudi S, Bayrouti MI, Daoud J, et al. Prognostic factors in metastatic colorectal cancer in Tunisia: a retrospective study of 130 patients. Tunis Med. 2015;93(1):11–5.PubMed
31.
Eker B, Ozaslan E, Karaca H, Berk V, Bozkurt O, Inanc M, et al. Factors affecting prognosis in metastatic colorectal cancer patients. Asian Pac J Cancer Prev. 2015;16(7):3015–21.CrossRefPubMed
Metadata
Title
The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
Authors
M. Ozcelik
H. Odabas
O. Ercelep
S. Yuksel
A. G. Mert
D. Aydin
H. Surmeli
D. Isik
S. Isik
A. Oyman
B. B. Oven Ustaalioglu
M. Aliustaoglu
M. Gumus
Publication date
01-06-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1408-6

Other articles of this Issue 6/2016

Clinical and Translational Oncology 6/2016 Go to the issue

Research Article

Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients

Research Article

The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma

Review Article

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

Research Article

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

Research Article

Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer

Erratum

Erratum to: Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits